Wellington Management Group LLP Grows Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Wellington Management Group LLP raised its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 763.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,725,622 shares of the company's stock after acquiring an additional 1,525,845 shares during the quarter. Wellington Management Group LLP owned about 1.84% of Scholar Rock worth $74,581,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Intech Investment Management LLC bought a new position in Scholar Rock during the 3rd quarter worth approximately $202,000. Charles Schwab Investment Management Inc. increased its holdings in Scholar Rock by 9.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company's stock worth $4,027,000 after buying an additional 42,139 shares during the last quarter. FMR LLC increased its holdings in shares of Scholar Rock by 3.1% in the third quarter. FMR LLC now owns 10,196,046 shares of the company's stock valued at $81,670,000 after purchasing an additional 308,813 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Scholar Rock by 900.6% in the third quarter. BNP Paribas Financial Markets now owns 36,331 shares of the company's stock valued at $291,000 after purchasing an additional 32,700 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Scholar Rock by 7.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock valued at $759,000 after purchasing an additional 6,269 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

Scholar Rock Stock Performance

SRRK traded down $1.61 during trading hours on Thursday, hitting $25.45. The stock had a trading volume of 179,632 shares, compared to its average volume of 1,203,000. The company's fifty day simple moving average is $34.72 and its 200 day simple moving average is $34.25. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The stock has a market cap of $2.41 billion, a PE ratio of -10.88 and a beta of 0.56. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63.

Wall Street Analysts Forecast Growth

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Scholar Rock currently has an average rating of "Buy" and an average price target of $42.67.

Insiders Place Their Bets

In other Scholar Rock news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the transaction, the director now directly owns 30,319 shares of the company's stock, valued at $1,043,579.98. The trade was a 3.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tracey Sacco sold 6,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the transaction, the insider now owns 71,750 shares of the company's stock, valued at approximately $2,373,490. This represents a 8.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 299,772 shares of company stock worth $11,245,798 in the last quarter. 19.20% of the stock is owned by company insiders.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.